Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib and Cyclophosphamide for GVHD Prophylaxis in Haploidentical Stem Cell Transplant
NCT03850366Phase 2Recruiting
- Sponsor
- Henry Ford Health
- Start
- Mar 2016
- Primary completion
- Jan 2028
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in graft-versus-host disease (GVHD), sponsored by Henry Ford Health. Started Mar 2016; status: recruiting.
02
Drugs
bortezomib
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT03850366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03850366.